Want to see SE:VIVE full AI Analyst Report?
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr7.00 - kr23.81
Previous CloseN/A
Volume772.68K
Average Volume (3M)7.32K
Market Cap
kr82.92M
Enterprise Valuekr70.59M
Total Cash (Recent Filing)kr23.51M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding11,071,369
10 Day Avg. Volume6,142
30 Day Avg. Volume7,317
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity CushionA debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Improving Loss And Cash-burn TrendThe substantial reduction in operating cash burn from prior years indicates better cost control or a more focused operating base. While cash generation remains negative, continued improvement could extend liquidity and reduce the amount of external capital needed to advance the pipeline.
Focused Oncology Development PlatformA focused oncology strategy gives Vivesto a defined therapeutic area and the potential to create value through differentiated drug candidates or delivery technologies. If development succeeds, partnering or commercialization could provide milestone, royalty, or product revenue opportunities.
Bears Say
Near-zero Revenue BaseNear-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.
Persistent Negative Cash Generation持续 negative operating and free cash flow means the company continues consuming liquidity while its pipeline is developed. This constrains investment flexibility and creates a durable need for financing or partnering, particularly if development expenses rise before revenue begins.
Ongoing Operating LossesMaterial recurring losses indicate that Vivesto has not reached positive earnings or demonstrated a stable path to profitability in its reported results. Narrower losses are encouraging, but continued deficits can erode the equity base and increase dependence on future funding.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr7.00 and its highest was kr23.81 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr82.92M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on Aug 13, 2026. The company reported -kr0.757 earnings per share for the quarter.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.757 in its last earnings report. Following the earnings report the stock price went up 3.691%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
SpectraCure AB
―
Nanologica AB
―
Spago Nanomedical AB
―
Nanexa AB
―